Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2007

View Archived Issues

New data on oblimersen pharmacokinetics, in vivo activity reported

New agents for treating neurological disorders disclosed in recent patents

Pharmacokinetics, pharmacodynamics of fospropofol studied

CNTNAP2 may be a candidate gene for autism

Nereus Pharmaceuticals' NPI-0052, NPI-2358 assessed in phase I cancer studies

Oxaliplatin formulation MBP-426 well tolerated in phase I study

Celtic Pharma completes enrollment in phase IIb TA-NIC study

Coley and Pfizer nominate second TLR9 agonist for clinical development

N30 Pharma enters S-nitrosothiol license agreement with NitroMed

Ipsen and Debiopharm extend their commercialization agreement for Decapeptyl

Gene Logic changes name to Ore Pharmaceuticals and sells genomics assets

Organon enters license agreement with Endotis for antithrombotic compounds

Apthera completes end of phase II meeting with FDA for NeuVax for breast cancer

Novo Nordisk licenses ghrelin antagonist program to Sapphire for treatment of obesity

ArQule initiates two phase II trials of ARQ-197

MAP initiates phase IIa clinical trial of MAP-0005 for asthma

Merck Serono signs agreement with the Ecole Polytechnique Federale de Lausanne

Nycomed signs partnership agreement with NPS to develop and commercialize Gattex

MedImmune and Seattle Genetics further their antibody-drug conjugate collaboration

Collegium successfully completes proof-of-concept study for oral oxycodone COL-003

FibroGen reports novel HIF prolyl hydroxylase inhibitors in a recent patent

Recent patents describe new treatment options for diabetes and associated disorders

Toll-like receptor 3 may be involved in the pathogenesis of Alzheimer's disease

GSK launches Atriance for treatment of lymph cancer

Novartis launches Exelon transdermal patch for treatment of Alzheimer's dementia

Bayer temporarily suspends worldwide marketing of Trasylol

Selective muscarinic agonists with potential for neurological disorders presented at SfN

Choline derivative a potential candidate for neurodegenerative and cognition disorders

Selective nAChR allosteric modulator safe and effective in improving cognition in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...